VTGNHIGH SIGNALFINANCIAL10-K

VTGN's financial position deteriorated significantly with operating losses nearly doubling to $56M while cash reserves declined 44% to $67.1M, raising concerns about runway and operational sustainability.

The company is burning through cash at an accelerated rate with operating cash flow worsening 63% to -$42.1M, while simultaneously increasing R&D spending by 97% to $39.4M for their late-stage pherine pipeline. With cash declining from $119M to $67M and current liabilities increasing 146%, investors should closely monitor the company's funding runway and potential need for additional capital raises.

Comparing 2025-06-17 vs 2024-06-11View on EDGAR →
FINANCIAL ANALYSIS

VTGN's financial metrics show severe deterioration across all key areas, with net losses expanding 75% to -$51.4M driven primarily by a 97% increase in R&D expenses to $39.4M, while revenue turned negative at -$227K. The balance sheet weakened substantially as cash reserves fell 44% to $67.1M and current liabilities surged 146% to $12.6M, though total debt was largely eliminated. Combined with operating cash flow deteriorating 63% to -$42.1M, the overall picture signals significant cash burn acceleration that could pressure the company's funding runway despite their late-stage clinical progress.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+300%
$2K$8K

Interest expense surged 300% — significant debt increase or rising rates materially impacting earnings.

Revenue
P&L
-226.1%
$180K-$227K

Revenue declined 226.1% — significant demand weakness or market share loss warrants investigation.

Current Liabilities
Balance Sheet
+146.2%
$5.1M$12.6M

Current liabilities surged 146.2% — significant near-term obligations; verify ability to meet short-term debt.

Total Debt
Balance Sheet
-97.4%
$2.2M$59K

Debt reduced 97.4% — deleveraging strengthens balance sheet and reduces financial risk.

R&D Expense
P&L
+96.7%
$20.0M$39.4M

R&D investment increased 96.7% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
-75.1%
-$29.4M-$51.4M

Net income declined 75.1% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-69.5%
-$33.0M-$56.0M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Operating Cash Flow
Cash Flow
-63.1%
-$25.8M-$42.1M

Operating cash flow fell 63.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Total Liabilities
Balance Sheet
+48.9%
$9.4M$14.0M

Liabilities grew 48.9% — significant increase in debt or obligations, assess impact on financial flexibility.

Cash & Equivalents
Balance Sheet
-43.7%
$119.2M$67.1M

Cash declined 43.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

LANGUAGE CHANGES
NEW — 2025-06-17
PRIOR — 2024-06-11
ADDED
As of June 10, 2025, there were 29,157,733 s hares of the registrant s common stock, $0.001 par value per share, outstanding.
Business Overview We are a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of non-systemic intranasal product candidates called pherines.
Our broad and diverse neuroscience pipeline currently consists of five clinical-stage pherine product candidates, each with a novel mechanism of action (MOA) and positive clinical data in their targeted indication(s).
Pherines specifically and selectively bind to peripheral receptors in human nasal chemosensory neurons, and are designed to rapidly activate nose-to-brain neurocircuits believed to regulate brain areas without requiring systemic absorption or uptake into the brain to achieve desired therapeutic benefits.
Our most advanced intranasal pherine product candidate is fasedienol, which is being investigated in our U.S.
+7 more — sign up free →
REMOVED
As of June 7, 2024, there were 27,025,209 shares of the registrant s common stock, $0.001 par value per share, outstanding.
Business Overview We are a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on our deep understanding of nose-to-brain neurocircuitry.
Our clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines.
Designed exclusively as nasal sprays, each of our pherine product candidates is centered on our innovative approach to addressing neuroscience disorders with the nose as a new portal for the administration of novel, rapid-onset neuroactive therapies that do not require systemic absorption or binding to neurons in the brain to achieve desired therapeutic effects.
Microgram-level doses of our pherine nasal sprays rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain with a differentiated safety profile observed in all clinical studies completed to date.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →